We show you our most important and recent visitors news details UAE announces two-week treatment results for COVID-19 medicine Sotrovimab in the following article
Hind Al Soulia - Riyadh - ABU DHABI — The UAE's health ministry has announced the treatment results for Sotrovimab, an anti-viral treatment for severe COVID-19 cases in adults, pregnant women and children aged 12 and above who are at risk of progressing to severe symptoms and meet other relevant criteria.
The ministry has approved the use of Sotrovimab, which is produced by global biopharmaceutical company GlaxoSmithKline (GSK), after conducting the local evaluation. It has also been approved for emergency use by the US Food and Drug Administration.
Between June 16-29, Sotrovimab was administered to 658 patients with COVID-19, 46 percent of whom are citizens and 54 percent of whom are residents. About 59 percent of the patients are aged 50 or above.
More than 97.3 percent of recipients showed improvement within five to seven days and, as symptoms subsided, neared full recovery. Patients receiving Sotrovimab fall within at-risk groups due to other comorbidities that have been associated with severe COVID-19, such as obesity, cancer, kidney disease, lung disease, cardiovascular disease, diabetes, hypertension and allergies.
Sotrovimab is a monoclonal antibody treatment delivered through intravenous therapy in accordance with protocols developed by the National Scientific Committee.
The UAE was one of the first countries in the world to receive a shipment of Sotrovimab in mid-June.
These were the details of the news UAE announces two-week treatment results for COVID-19 medicine Sotrovimab for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.
It is also worth noting that the original news has been published and is available at Saudi Gazette and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.